XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.


Creative Commons License

UYGUN K., BILICI A., KAYA S., Oven U., YILDIZ R., TEMIZ S., ...Daha Fazla

Asian Pacific journal of cancer prevention : APJCP, cilt.14, ss.2283-8, 2013 (SCI-Expanded, Scopus) identifier identifier identifier